- Quotient Sciences has established a Scientific Advisory Board (SAB) and appointed four founding members from the US, UK, and Europe.
- The SAB will support the company’s scientific and executive leadership in shaping R&D priorities and scientific strategy.
Quotient Sciences, a contract research, development, and manufacturing organisation (CRDMO), has announced the formation of its first Scientific Advisory Board (SAB), with four distinguished experts appointed as founding members.
The SAB aims to strengthen the company’s commitment to scientific excellence by providing strategic guidance on research priorities, technology investments, and overall scientific direction. The board will work in close collaboration with Quotient Sciences’ leadership teams.
The founding members include Dr. Dominique Demolle, CEO of Cognivia; Dr. Alastair Coupe, Independent CMC Consultant; Dr. Colin Rowlings, SVP of CMC at Actio Biosciences; and Professor Yvonne Perrie, Chair in Drug Delivery at the University of Strathclyde. Each brings extensive experience in pharmaceutical development, manufacturing, and drug delivery systems.
The new board combines industry, academic, and regulatory expertise. Among the appointees, Professor Perrie was recently named an MBE for services to pharmaceutical innovation and regulation, and Dr. Demolle was recognised by PharmaVoice in 2022 for her contributions to life sciences.
“The collective experience and insight of the SAB will be invaluable as we continue to expand our technology and service offering,” said Dr. Andy Lewis, Chief Scientific Officer, Quotient Sciences.
